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Abstract
Background: The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. 
Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk 
of common cancers. However, the relationship between these two functional polymorphisms and nasopharyngeal 
carcinoma (NPC) susceptibility has not been explored.
Methods: In this study, we performed a case-control study between 522 NPC patients and 722 healthy controls in a 
Chinese population by using PCR-RFLP.
Results: We found an increased NPC risk associated with the MDM2 GG (odds ratio [OR] = 2.83, 95% confidence interval 
[CI] = 2.08-3.96) and TG (OR = 1.49, 95% CI = 1.16-2.06) genotypes. An increased risk was also associated with the TP53 
Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. The gene-gene interaction of 
MDM2 and TP53 polymorphisms increased adult NPC risk in a more than multiplicative manner (OR for the presence of 
both MDM2 GG and TP53 Pro/Pro genotypes = 7.75, 95% CI = 3.53-17.58).
Conclusion: The findings suggest that polymorphisms of MDM2 and TP53 genes may be genetic modifier for 
developing NPC.
Background
As an important tumor suppressor, TP53 protein level is
low or undetectable in normal cells, but diverse forms of
stress may trigger its production, resulting in either cell
cycle arrest or apoptotic cell death [1,2]. High frequencies
of TP53 mutation and/or deletion are found in a wide
variety of human malignancies, including nasopharyn-
geal carcinoma (NPC), which is believed to be contrib-
uted to tumorigenesis and progression [3-5].
Recently, Bond et al. reported that a T>G polymor-
phism at position 309 downstream from MDM2 intron 1
disrupts an Sp1 regulatory element and the T allele thus
has a strikingly lower promoter activity compared with
the G allele [6]. Moreover, a single nucleotide polymor-
phism has been identified in the coding region of TP53,
which causes an Arg72>Pro amino acid substitution [7].
It has been shown that, compared with Pro allele, the Arg
allele is faster to induce apoptosis and more efficient in
suppressing transformation. Many molecular epidemio-
logic data found that these two polymorphisms are likely
candidate genetic markers of certain cancers [8-10].
However, the gene-gene interaction of these two poly-
morphisms in MDM2 and TP53 has not been examined
in NPC studies to date. Because of their significant
impact in several tumors, these two polymorphisms
might also affect the function of MDM2 and TP53 and
play an important role in NPC development. These two
polymorphisms might impact individual susceptibility to
carcinogenesis. Based on this hypothesis, we carried out a
hospital-based case-control study to investigate the rela-
tionship between polymorphisms in MDM2 309T>G and
TP53 Arg72Pro and the risk of NPC in Chinese popula-
tion.
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Methods
Study Subjects
This study included 522 NPC patients and 712 healthy
population controls. All subjects were ethnically homog-
enous Han Chinese. Patients with newly diagnosed NPC
were consecutively recruited from March 2001 to May
2007, at the Sir Run Run Shaw Hospital, Zhejiang Univer-
sity (Hangzhou) and Zhejiang Cancer Hospital (Hang-
zhou). All eligible patients diagnosed at the hospital
during the study period were recruited, with a response
rate of 94%. Patients were from Hangzhou city and its
surrounding regions and there were no age, stage, and
histology restrictions. The tumor, node, metastasis
(TNM) classification and tumor staging was evaluated
according to the 2002 American Joint Committee on
Cancer staging system [11]. The clinical features of the
patients are summarized in Table 1. Population controls
were cancer-free people living in Hangzhou region; they
were selected from a nutritional survey conducted in the
same period as the cases were collected. The control sub-
jects were randomly selected from a database consisting
of 2500 individuals based on a physical examination. The
selection criteria included no history of cancer and fre-
quency matched to cases on age and sex. Median age was
46 years (range 26-81) for case patients and 47 years
(range 22-85) for control subjects (P = 0.78). At recruit-
ment, informed consent was obtained from each subject.
This study was approved by the Medical Ethics Commit-
tee of Sir Run Run Shaw Hospital and Zhejiang Cancer
Hospital.
Polymorphism analysis
Genomic DNA was isolated from the peripheral blood
lymphocytes of the study subjects. Genotypes were ana-
lyzed using PCR-based methods as described below.
Genotyping was performed without knowledge of sub-
jects' case/control status. A 30% masked, random sample
of cases and controls was tested twice by different per-
sons and the results were concordant for all masked
duplicate sets.
The genotypes of TP53  Arg72Pro (rs1042522, G>C)
were analyzed by PCR-RFLP method on the basis of that
reported previously [12]. The primers used were TP53 F,
5'-TTG CCG TCC CAA GCA ATG GAT GA-3' and TP53
R, 5'-TCT GGG AAG GGA CAG AAG ATG AC-3',
which produce a 199-bp fragment containing the G/C
site. Amplification was accomplished with a 25 μl reac-
Table 1: Distribution of selected characteristics by case-control status in NPC association analysis.
Cases Controls
n%n%
Sex
Male 315 60.3 404 56.7
Female 207 39.7 308 42.7
Age (years)
≤40 195 37.4 242 34.0
41-50 134 25.7 186 26.1
51-60 93 17.8 166 23.3
>60 100 19.1 118 16.6
Tumor stage
I 126 24.2
II 208 39.8
III 177 33.9
IV 11 2.1
EBV Infection status
Positive 329 63.1
Negative 162 31.0
Data missing 31 5.9
Metastasis
Present 283 54.2
Absent 239 45.8Xiao et al. BMC Cancer 2010, 10:147
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tion mixture containing ~100 ng template DNA, 0.5 μM
each primer, 0.2 mM each dNTP, 1.5 mM MgCl2, and 1.2
units of Taq  DNA polymerase with 1 × Reaction buffer
(Promega, Madison, WI, USA). PCR profile consisted of
an initial melting step of 2 min at 94°C, followed by 35
cycles of 30 s at 94°C, 30 s at 56°C, and 30 s at 72°C, and a
final elongation step of 7 min at 72°C. The 199-bp PCR
products were then subject to the digestion with BstUI
(New England Biolabs, UK) and separated on a 3.0% aga-
rose gel. The genotypes identified by BstUI digestion
were confirmed by DNA sequencing (Figure 1).
MDM2 SNP309 (rs2279744, T>G) genotypes were ana-
lyzed using the tetra-primer amplification refractory
mutation system (ARMS)-PCR method [13]. The primers
for ARMS-PCR amplification of DNA fragment contain-
ing the MDM2 SNP309 T allele were MDM2 F1: 5'-GGG
GGC CGG GGG CTG CGG GGC CGT TT-3' and
MDM2  R1: 5'-TGC CCA CTG AAC CGG CCC AAT
CCC GCC CAG-3'; For the MDM2 SNP309 G allele they
were  MDM2  F2: 5'-GGC AGT CGC CGC CAG GGA
GGA GGG CGG-3' and MDM2 R2: 5'-ACC TGC GAT
CAT CCG GAC CTC CCG CGC TGC-3'. The amplifica-
tion was accomplished with a 10-μl reaction mixture con-
taining 10 ng of template DNA, 0.8 μM of primers
MDM2 F1 and MDM2 R1, 4.8 μM of primers MDM2 F2
and MDM2 R2, 0.2 mM of dNTPs, 1.5 mM of MgCl2, and
0.4 U of HotStar TaqTM with 1 × buffer and 1 × Q-solu-
tion (Qiagen, Chatsworth, CA). The reaction was carried
out with an initial melting step of 15 min at 95°C, fol-
lowed by 35 cycles of 45 sec at 95°C, 45 sec at 64°C, and 1
min at 72°C, and a final elongation step of 7 min at 72°C.
The amplified DNA was visualized on agarose gel con-
taining ethidium bromide. The MDM2 SNP309 T allele
generated a 122-bp band, and the G allele generated a
158-bp band. They had a common 224-bp band, which
was amplified by primers MDM2 F2 and MDM2 R1. The
genotypes identified by PCR-RFLP and ARMS-PCR
digestion were confirmed by DNA sequencing (Figure 2).
Real-time analysis of MDM2 mRNA
Total RNA was isolated from Seventy-one NPC tissues
using the Trizol reagent (Molecular Research Center,
Inc., Cincinnati, OH) and converted to cDNA using an
oligo (dT)15 primer and Superscript II (Invitrogen, Carls-
bad, CA). Relative gene expression quantitation for
MDM2, with β-actin as an internal reference gene, was
carried out using ABI Prism 7300 sequence detection sys-
tem (Applied Biosystem, Foster City, CA) in triplicates,
based on the SYBR-Green method [8]. The primers used
for MDM2 were 5'-TGT AAG TGA ACA TTC AGG TG-
3' and 5'-TTC CAA TAG TCA GCT AAG GA-3'; and for
β-actin were 5'-GGC GGC ACC ACC ATG TAC CCT-3'
and 5'-AGG GGC CGG ACT CGT CAT ACT-3'. The
PCR reaction mixture consisted of 0.1 μmol/L of each
primer, 1 × SYBR Premix EX Taq (Perfect Real Time) pre-
mix reagent (TaKaRa, Dalian, China), and 50 ng cDNA to
a final volume of 20 μL. Cycling conditions were 95°C for
10 minutes, followed by 40 cycles at 95°C of 15 seconds
and 62°C for 1 minute. PCR specificity was confirmed by
dissociation curve analysis and gel electrophoresis. All
analysis were done in a blinded fashion with the labora-
tory persons unaware of genotyping data. The expression
of individual MDM2 measurements was calculated rela-
tive to expression of β-actin using a modification of the
method described by Lehmann et al [14].
Statistical Analysis
χ2 tests were used to examine the differences in the distri-
butions of genotypes between cases and controls. The
association between the TP53  and  MDM2  polymor-
phisms and risk of NPC were estimated by ORs and their
Figure 1 Representative PCR-RFLP for different genotypes con-
taining the TP53 Arg72Pro polymorphism site and DNA sequenc-
ing analysis. (A) M: DNA size markers; lane 1, 2, 4 and 5: TP53 72Pro/Pro; 
lane 6, 7 and 8: TP53 72Arg/Pro; lane 3: TP53 72Arg/Arg. (B) The PCR 
products with different PCR-RFLP profiles were sequenced to confirm 
the genotypes.
 
Figure 2 Representative tetraprime ARMS-PCR for different gen-
otypes containing the MDM2 SNP309 T>G polymorphism site 
and DNA sequencing analysis. (A) M: DNA size markers; lane 1, and 9: 
MDM2 309TT; lane 2, 3, 4, 6 and 8: MDM2 309TG; lane 5 and 7: MDM2 
309TT. (B) The PCR products with different tetraprime ARMS-PCR pro-
files were sequenced to confirm the genotypes.
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95% CIs, which were calculated by unconditional logistic
regression models. We tested the null hypotheses of mul-
tiplicative gene-gene interactions by evaluated departures
from multiplicative joint effect models by including main
effect variables and their product terms in the logistic
regression model [15]. A more-than-additive interaction
was suggested when OR11 > OR10 + OR01 -1, for which
OR11 = OR when both factors were present, OR10 = OR
when only factor 1 was present and OR01 = OR when only
factor 2 was present. A more-than-multiplicative interac-
tion was suggested when OR11 >OR10 ×OR01. The correla-
tion of genotypes and clinical parameters was analyzed
via the Fisher's exact test or χ2 test as appropriate. The
normalized expression values of MDM2 were compared
by Kruskal-Wallis one way ANOVA. All P-values were
two-sided with a P-value < 0.05 considered to be statisti-
cally significant. All analysis was carried out with Statisti-
cal Analysis System software (Version 9.0; SAS Institute,
Cary, NC, USA).
Results
Allele and Genotype Distribution
The genotype results are shown in Table 2. The allele fre-
quencies for MDM2 G and  TP53 Pro were 0.423 and
0.426 in controls, and 0.555 and 0.518 in cases respec-
tively. The observed genotype frequencies of MDM2 and
TP53 polymorphisms in both controls and cases did not
deviated from those expected from the Hardy-Weinberg
equilibrium. Distributions of these MDM2  and  TP53
genotype were then compared among cases and controls.
The frequencies of MDM2 TT, TG and GG genotypes
among patients were significantly different compared to
controls (Ptrend < 0.001), with the GG homozygotes being
significantly overrepresented among patients compared
to controls (P  < 0.001). Moreover, Logistic regression
analysis showed that subjects with TP53 Pro allele signifi-
cant increased risk of NPC compared with subjects carry-
ing the Arg  allele (OR for the Arg/Pro genotype, 1.43;
95%CI, 1.22-2.13; OR for the Pro/Pro genotype, 2.22;
95%CI, 1.58-3.10; Ptrend < 0.001), suggesting that the Pro
allele is the high-risk allele.
The effects of the TP53 and  MDM2  polymorphisms
were additionally examined with stratification by age,
tumor size, metastatic status and Epstein-Barr virus
(EBV) infection status. However, no significant associa-
tion was observed between age and the TNM stage at the
time of NPC diagnosis and the polymorphism of this
gene, and no interaction was detected between the poly-
morphism and status of EB virus infection (data not
shown).
Gene-Gene Interaction between MDM2 and TP53 
Polymorphisms
We examined whether there was a statistical interaction
between the MDM2 and TP53 polymorphisms (Table 3).
The data showed that patients who carried the MDM2
GG  ge no type  we r e  a lso  mo r e  li k e ly t o ca rry t he  TP53
Pro/Pro genotype than the controls (10.3% vs. 2.8%, P <
0.001). The presence of one MDM2 GG genotype, but not
one  TP53  Pro/Pro genotype, were associated with an
increased risk of NPC (OR = 2.83, 95% CI = 1.33-5.90),
compared to the lack of such a genotype. However, the
presence of both MDM2 GG and TP53 Pro/Pro geno-
types was associated with an even higher risk for NPC
Table 2: Genotype and allele frequencies of TP53 and MDM2 among cases and controls and their association with the risk 
of NPC.
Genotype Cases (n = 522) Controls (n = 712) OR* (95% CI)
no. (%) no. (%)
TP53 72Arg>Pro
Arg/Arg 117 (22.4) 226 (31.7) 1.00 (reference)
Arg/Pro 270 (51.7) 366 (51.4) 1.43 (1.22-2.13)
Pro/Pro 135 (25.9) 120 (16.9) 2.22 (1.58-3.10)
Pro allele frequency 0.518 0.426
MDM2 309T>G
TT 111 (21.2) 238 (33.4) 1.00 (reference)
TG 243 (46.6) 346 (48.6) 1.49 (1.16-2.06)
GG 168 (32.2) 128 (18.0) 2.83 (2.08-3.96)
G allele frequency 0.555 0.423
*OR and 95%CI were calculated by unconditional logistic regression, with TP53 Arg/Arg or MDM2 TT genotype as the reference group and 
adjusted by sex and age.Xiao et al. BMC Cancer 2010, 10:147
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increase (OR = 7.75, 95% CI = 3.53-17.58; P < 0.05, test
for homogeneity) compared to those who lacked both
genotypes. These results clearly indicate a more than
multiplicative interaction [15] between the MDM2 GG
and  TP53  Pro/Pro genotype in the risk of developing
NPC.
MDM2 RNA Levels in NPC tissues from Different Genotype 
Carriers
To examine the effect of the MDM2 309T>G polymor-
phism on MDM2 expression in the target tissues, the lev-
els of MDM2  mRNA in individual NPC tissues were
quantified by real-time PCR (Figure 3). The results
showed that the MDM2 GG genotype carriers (n = 19)
had significantly higher MDM2  mRNA level than the
MDM2 TT genotype carriers [0.050 ± 0.033 (n = 19) ver-
sus 0.014 ± 0.009 (n = 18), P  < 0.001]. However, the
MDM2  TG genotype carriers (n = 34) had a MDM2
mRNA level that was very similar to that of the TT geno-
type carriers (0.015 ± 0.013 versus 0.014 ± 0.009, P  =
0.610).
Discussion
In the present study, our group found that MDM2 and
TP53 polymorphisms may influence the development of
NPC in a Chinese population. On the basis of examining
522 cases and 712 controls, our data showed that MDM2
309GG, which increase MDM2 expression level in NPC
tissue, and TP53 72Pro/Pro genotypes were statistically
significantly associated with increased risk of NPC. In
addition, the association between these two polymor-
phisms and the risk of NPC displayed a multiplicative
gene-gene interaction, which rendered the subjects car-
rying both MDM2  309GG and TP53  72Pro/Pro geno-
types at much higher risk for developing NPC.
Our results showing an association between risk of
NPC and polymorphisms of MDM2 and TP53 are biolog-
ically plausible for the following reasons. Firstly, there is
broad evidence suggesting that TP53  is a key gene in
maintaining genomic integrity and preventing tumori-
genesis [16-19]. The association between mutation of
TP53 and susceptibility to tumor formations has been
tested in several studies with genetically modified ani-
mals. It was found that mice lacking the inactivating
mutation in one tp53 allele developed fewer tumors than
mice harboring it and they developed tumors very early
in life and at very high frequencies [20]. Moreover, over-
expression of MDM2, which can led to loss of TP53 activ-
ity, was also observed in a variety of tumors with diverse
tissue origins [21,22]. Secondly, the investigated polymor-
Table 3: Risk of NPC associated with MDM2 genotypes by TP53 genotypes.
Genotype Cases Controls OR* (95% CI)
MDM2 309T>G TP53 72Arg>Pro no. (%) no. (%)
TT Arg/Arg 24 (4.6) 68 (9.6) 1.00 (reference)
Arg/Pro 63 (12.1) 128 (18.0) 1.34 (0.75-2.48)
Pro/Pro 24 (4.6) 42 (5.9) 1.63 (0.81-3.42)
TG Arg/Arg 54 (10.3) 120 (16.9) 1.30 (0.72-2.39)
Arg/Pro 132 (25.3) 168 (23.6) 2.12 (1.90-3.86)
Pro/Pro 57 (10.9) 58 (8.1) 2.91 (1.53-5.31)
GG Arg/Arg 39 (7.5) 38 (5.3) 2.83 (1.33-5.90)
Arg/Pro 75 (14.4) 70 (9.8) 3.13 (1.61-5.94)
Pro/Pro 54 (10.3) 20 (2.8) 7.75 (3.53-17.58)
* Data were calculated by unconditional logistic regression, adjusting for sex and age status.
Figure 3 MDM2 mRNA expression level in NPC tissue as function 
of MDM2 genotype. Columns, mean; bars, ± SD normalized to β-actin. 
Expression level among the GG genotype was significantly different 
from that among the GT or TT genotype (P < 0.05).Xiao et al. BMC Cancer 2010, 10:147
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phisms in the TP53 and MDM2 genes have functional
consequences [6,7,23]. Our real-time PCR finding is con-
sistent with recent reports by Bond et al. and Hong et al
[6,8] that the MDM2 309GG genotype carriers had signif-
icantly higher MDM2 expression in NPC tissues than the
TT and TG genotype carriers, suggesting the variant
MDM2 genotype may cause attenuated TP53 function.
Several case-control studies have examined the associa-
tion between these two polymorphisms and many tumor
types, but the results are conflicting [8,9,24-27]. A meta-
analysis of 21 studies showed that ORs of a variety of can-
cers associated with the MDM2 GG and TG genotype
were 1.17 (95% CI = 1.04-1.33) and 1.15 (95% CI = 1.03-
1.28), respectively [28]. Moreover, another meta-analysis
study reported that the TP53  Pro/Pro polymorphisms
was significantly increase susceptibility to NPC [29].
Phang et al. reported in a study conducted in Singapore
Chinese that the MDM2 309SNP was not associated with
leukemia [30]. However, Xiong et al. also found an
increased risk of acute myeloid leukemia (AML) associ-
ated with MDM2 309GG genotype [9]. Zhou et al. shown
that MDM2 309SNP may be a risk factor for occurrence
of NPC [31]. Moreover, the control frequencies of TP53
Arg72Pro and MDM2 SNP309 in our present study were
similar with Asian population in published papers
[28,29]. Our study provided strong molecular epidemio-
logic evidence to support the hypothesis that TP53
72Arg/Pro and MDM2  309T>G polymorphisms also
affect the development of NPC.
Although it is generally believed that TP53 pathway
also plays a critical role in tumor aggressive course
[32,33], we did not find significant correlations between
TP53 and MDM2 genotypes and the prognosis status of
NPC in the present study. These results suggest that the
examined polymorphisms in TP53 and MDM2 might not
serve as a sole risk marker of prognosis. Further examina-
tions of larger patient series with prospectively follow-up
clinical outcomes especially the survival rates may be
required. Moreover, our study may have certain limita-
tions because of the study design. Selection bias and/or
systematic error may occur because the cases were from
the hospital and the controls were from the community.
Some factors which may interact with genotype or act as
potential confounders in analysis such as information of
nutrition is not available in our case-control study.
Conclusion
The current study demonstrated a significant association
between the TP53 72Arg/Pro and MDM2 309T>G poly-
morphisms and the risk of developing NPC for the first
time. The association of MDM2 polymorphism with the
risk of NPC displayed a multiplicative gene-gene interac-
tion with the TP53  72Arg/Pro polymorphism. These
molecular epidemiology findings are consistent with the
results obtained from the functional analysis. Because
MDM2  overexpression and high frequencies of TP53
mutation are found in many tumor types, additional stud-
ies on other tumor types would be warranted. Moreover,
the possible role of these polymorphisms in disease prog-
nosis should also be addressed in the future studies.
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